Intellia Therapeutics
NTLA
290 hedge funds and large institutions have $3.19B invested in Intellia Therapeutics in 2023 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 108 increasing their positions, 73 reducing their positions, and 34 closing their positions.
48% more repeat investments, than reductions
Existing positions increased: 108 | Existing positions reduced: 73
9% more capital invested
Capital invested by funds: $2.93B → $3.19B (+$261M)
0% less funds holding
Funds holding: 291 → 290 (-1)
0.64% less ownership
Funds ownership: 89.45% → 88.8% (-0.64%)
3% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 34
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
52% less call options, than puts
Call options by funds: $15.1M | Put options by funds: $31.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$28.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$17.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.3M |
| 4 |
CIM
Contrarius Investment Management
St. Helier,
Jersey
|
+$11.9M |
| 5 |
NAMA
Nikko Asset Management Americas
New York
|
+$11.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$58.5M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$37.7M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
-$22.6M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$14.2M |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$12.6M |
NTLA Hedge Fund Activity: Q2 2023 in Review
290 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q2 2023, worth a combined $3.19B — up 8.9% from $2.93B a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of NTLA and 33 opened new positions — a net loss of 1 holder — while 73 trimmed existing stakes and 108 added.
The largest buyer was BlackRock, adding an estimated $28.6M. The largest seller was Viking Global Investors, exiting entirely with an estimated $58.5M sold.
- 290 institutional investors held Intellia Therapeutics (NTLA) as of Q2 2023, down from 291 in Q1 2023.
- Funds reported $3.19B of Intellia Therapeutics stock for Q2 2023, up 8.9% quarter-over-quarter.
- 33 funds opened new Intellia Therapeutics positions in Q2 2023 and 34 closed out, a net change of -1 holder.
- The largest Intellia Therapeutics buyer in Q2 2023 was BlackRock, an estimated $28.6M added.
- The largest Intellia Therapeutics seller in Q2 2023 was Viking Global Investors, an estimated $58.5M sold.
Based on aggregated 13F filings for Q2 2023.